1. |
中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南.中华结核和呼吸杂志,2006,29:651-655.
|
2. |
徐作军,丁可,黄慧,等.社区获得性肺炎诊断和治疗指南临床应用调查及490例病例分析.中华结核和呼吸杂志,2007,30:442-446.
|
3. |
Fernández González F, Detrés J, Torrellas P, et al. Comparison of the appropriate use of antibiotics based on clinical guidelines between physicians in-training versus practicing physicians. Bol Asoc Med P R,2013,105:21-24.
|
4. |
Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections:cluster-randomised, single-blinded intervention trial. Lancet,2004,363:600-607.
|
5. |
Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections:the ProHOSP randomized controlled trial. JAMA,2009,302:1059-1066.
|
6. |
Horie M, Ugajin M, Suzuki M, et al. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia. Am J Med Sci,2012,343:30-35.
|
7. |
Kirtland SH, Winterbauer RH. Slowly resolving, chronic, and recurrent pneumonia. Clin Chest Med,1991,12:303.
|
8. |
Remington LT, Sligl WI.Community-acquired pneumonia. Curr Opin Pulm Med,2014,20:215-224.
|
9. |
Menéndez R, Martínez R, Reyes S, et al.Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax,2009,64:587-591.
|
10. |
Valencia M, Badia JR, Cavalcanti M, et al. Pneumonia severity index class V patient with community-acquired pneumonia:characteristics, outcomes and value of severity scores. Chest,2007,132:515-522.
|
11. |
Buising KL, Thursky KA, Black JF, et al. A prospective comparison of severity scores for identifying patients with severe community-acquired pneumonia:reconsidering what is meant by severe pneumonia. Thorax,2006,61:419-424.
|
12. |
Lim WS. Severity assessment in community-acquired pneumonia:moving on. Thorax,2007,62:287-288.
|
13. |
Hohenthal U, Hurme S, Helenius H, et al. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. Clin Microbiol Infect,2009,15:1026-1032.
|
14. |
Manma P, Nedelnikova K, Gurlich R, et al. Physiology and genetics of procalcitonin. Physiol Res,2000,49(Suppl):S57-S61.
|
15. |
Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections:an individual patient data meta-analysis. Clin Infect Dis,2012,55:651-662.
|
16. |
Dusemund F,Bucher B, Meyer S, et al. Influence of procalcitonin on decision to start antibiotic treatment in patients with a lower respiratory tract infection:insight from the observational multicentric ProREAL surveillance. Eur J Clin Microbiol Infect Dis,2013,32:51-60.
|
17. |
Kristoffersen KB, Søgaard OS, Wejse C, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission--a randomized trial. Clin Microbiol Infect,2009,15:481-487.
|
18. |
Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis,2007,7:10-12.
|